BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 30760052)

  • 1. RNA Interference Therapy for Machado-Joseph Disease: Long-Term Safety Profile of Lentiviral Vectors Encoding Short Hairpin RNAs Targeting Mutant Ataxin-3.
    Nóbrega C; Codêsso JM; Mendonça L; Pereira de Almeida L
    Hum Gene Ther; 2019 Jul; 30(7):841-854. PubMed ID: 30760052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
    Gonçalves N; Simões AT; Cunha RA; de Almeida LP
    Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing mutant ataxin-3 rescues motor deficits and neuropathology in Machado-Joseph disease transgenic mice.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Hirai H; Déglon N; de Almeida LP
    PLoS One; 2013; 8(1):e52396. PubMed ID: 23349684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.
    Alves S; Régulier E; Nascimento-Ferreira I; Hassig R; Dufour N; Koeppen A; Carvalho AL; Simões S; de Lima MC; Brouillet E; Gould VC; Déglon N; de Almeida LP
    Hum Mol Genet; 2008 Jul; 17(14):2071-83. PubMed ID: 18385100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of the calpain-generated toxic fragment of ataxin-3 protein provides new avenues for therapy of Machado-Joseph disease| Spinocerebellar ataxia type 3.
    Simões AT; Carmona V; Duarte-Neves J; Cunha-Santos J; Pereira de Almeida L
    Neuropathol Appl Neurobiol; 2022 Feb; 48(1):e12748. PubMed ID: 34273111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unravelling Endogenous MicroRNA System Dysfunction as a New Pathophysiological Mechanism in Machado-Joseph Disease.
    Carmona V; Cunha-Santos J; Onofre I; Simões AT; Vijayakumar U; Davidson BL; Pereira de Almeida L
    Mol Ther; 2017 Apr; 25(4):1038-1055. PubMed ID: 28236575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-establishing ataxin-2 downregulates translation of mutant ataxin-3 and alleviates Machado-Joseph disease.
    Nóbrega C; Carmo-Silva S; Albuquerque D; Vasconcelos-Ferreira A; Vijayakumar UG; Mendonça L; Hirai H; de Almeida LP
    Brain; 2015 Dec; 138(Pt 12):3537-54. PubMed ID: 26490332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropeptide Y mitigates neuropathology and motor deficits in mouse models of Machado-Joseph disease.
    Duarte-Neves J; Gonçalves N; Cunha-Santos J; Simões AT; den Dunnen WF; Hirai H; Kügler S; Cavadas C; Pereira de Almeida L
    Hum Mol Genet; 2015 Oct; 24(19):5451-63. PubMed ID: 26220979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
    Alves S; Nascimento-Ferreira I; Dufour N; Hassig R; Auregan G; Nóbrega C; Brouillet E; Hantraye P; Pedroso de Lima MC; Déglon N; de Almeida LP
    Hum Mol Genet; 2010 Jun; 19(12):2380-94. PubMed ID: 20308049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference mitigates motor and neuropathological deficits in a cerebellar mouse model of Machado-Joseph disease.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Déglon N; de Almeida LP
    PLoS One; 2014; 9(8):e100086. PubMed ID: 25144231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of mutant ataxin-3 in mouse cerebellum induces ataxia and cerebellar neuropathology.
    Nóbrega C; Nascimento-Ferreira I; Onofre I; Albuquerque D; Conceição M; Déglon N; de Almeida LP
    Cerebellum; 2013 Aug; 12(4):441-55. PubMed ID: 23242710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous administration of brain-targeted stable nucleic acid lipid particles alleviates Machado-Joseph disease neurological phenotype.
    Conceição M; Mendonça L; Nóbrega C; Gomes C; Costa P; Hirai H; Moreira JN; Lima MC; Manjunath N; Pereira de Almeida L
    Biomaterials; 2016 Mar; 82():124-37. PubMed ID: 26757259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
    Raj K; Akundi RS
    Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease.
    Nascimento-Ferreira I; Santos-Ferreira T; Sousa-Ferreira L; Auregan G; Onofre I; Alves S; Dufour N; Colomer Gould VF; Koeppen A; Déglon N; Pereira de Almeida L
    Brain; 2011 May; 134(Pt 5):1400-15. PubMed ID: 21478185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular vesicle-based delivery of silencing sequences for the treatment of Machado-Joseph disease/spinocerebellar ataxia type 3.
    Rufino-Ramos D; Albuquerque PR; Leandro K; Carmona V; Martins IM; Fernandes R; Henriques C; Lobo D; Faro R; Perfeito R; Mendonça LS; Pereira D; Gomes CM; Nobre RJ; Pereira de Almeida L
    Mol Ther; 2023 May; 31(5):1275-1292. PubMed ID: 37025062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease.
    Simões AT; Gonçalves N; Koeppen A; Déglon N; Kügler S; Duarte CB; Pereira de Almeida L
    Brain; 2012 Aug; 135(Pt 8):2428-39. PubMed ID: 22843411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors.
    Fish RJ; Kruithof EK
    BMC Mol Biol; 2004 Aug; 5():9. PubMed ID: 15291968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated Mesenchymal Stromal Cell Treatment Sustainably Alleviates Machado-Joseph Disease.
    Oliveira Miranda C; Marcelo A; Silva TP; Barata J; Vasconcelos-Ferreira A; Pereira D; Nóbrega C; Duarte S; Barros I; Alves J; Sereno J; Petrella LI; Castelhano J; Paiva VH; Rodrigues-Santos P; Alves V; Nunes-Correia I; Nobre RJ; Gomes C; Castelo-Branco M; Pereira de Almeida L
    Mol Ther; 2018 Sep; 26(9):2131-2151. PubMed ID: 30087083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse models of Machado-Joseph disease and other polyglutamine spinocerebellar ataxias.
    Colomer Gould VF
    NeuroRx; 2005 Jul; 2(3):480-3. PubMed ID: 16389311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.